Thermosensitive Hyaluronic Gel With Octenidine as an Adjunctive to Subgingival Instrumentation. Spontaneous, Postmarketing Trial With a Medical Device (MD), Split-mouth, Nationwide Multicenter Study Single-blind Randomized Controlled Trial

NCT07725913 | Recruiting

• 1 other identifier: 650-2025-DISP-AUSLBO
• Study Type: interventional
• Target: 40
• Locations: 1 country
• Sites: 2

Brief Summary

This will be a spontaneous, postmarketing trial with a medical device (MD), split-mouth, nationwide multicenter study (coordinator center: Periodontal Unit, Dental Clinic, DIBINEM, Bologna University, Italy, with satellite center involved), single-blind (examiner), randomized controlled trial comparing, at different time points, the clinical efficacy of PX-Gel-a thermosensitive hyaluronic acid-octenidine gel-in enhancing gingival healing of periodontal pockets when used as an adjunct to scaling and root planing (test group) versus conventional SRP (control group). SRP represents the gold standard for non-surgical treatment of periodontitis and it is the standard of care. Each patient will contribute with at least 4 sites with a PD more than 5 mm and positive BOP in 2 contralateral quadrants. The sites will be randomly assigned to one of the two treatment regimens, using a predetermined computer- generated randomization scheme, regarding left or right side) to receive the test treatment (SRP + PX-gel) or to serve as SRP controls. Allocation concealment will be performed by opaque sealed envelopes, sequentially numbered. The allocation sequence will be generated by means of a computer-generated random list (https ://www.sealedenve lope.com/simple-randomiser/ v1/) and a different subject (not involved in the treatment) will be instructed to assign a sealed envelope containing the treatments of each site (SRP+ PX-Gel or SRP). The opaque sealed envelope will be opened immediately after the end of the SRP session. Blinding of independent examiner will be maintained through-out all study period. The patients will not be informed of the locations where the treatment gel will be applied. All adult subjects referred to the Periodontal Unit and involved satellite center for periodontal treatment will be screened and enrolled in the study according to the following inclusion/exclusion criteria:

• Patients agreeing to participate in the study
• Age 18 years or older
• ≥ 20 existing teeth (wisdom teeth excluded).
• Diagnosis of periodontitis stage II-III or IV (any grade) of periodontitis
• Each participant should have 2 or more contralateral quadrants with a minimum of 4 qualifying pockets of ≥ 5 mm that bled on probing
• Full-mouth parallel periapical X-rays demonstrating bone loss (standard of care)

Conditions

Periodontal Disease

Outcome Measures

Primary Outcomes (1)

• • Pocket depth reduction

  will be measured using light probing force (approximately 25 gr) with a 1-mm periodontal probe at six sites around each tooth (mesiobuccal, midbuccal, distobuccal, mesiolingual, distolingual/palatal, midlingual/palatal). A full mouth periodontal chart is done at preliminary visit for screening and periodontal diagnosis.

  Baseline, 1-3-6 months

Study Arms (2)

Use of PX gel

EXPERIMENTAL

Px gel applied in periodontal pockets

Device: Use of px gel

No use of Px gel

PLACEBO COMPARATOR

No use of px gel

Device: Use of px gel

Interventions

Use of px gel DEVICE

use of px gel in periodontal pockets

No use of Px gel; Use of PX gel

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Patients agreeing to participate in the study
• Age 18 years or older
• ≥ 20 existing teeth (wisdom teeth excluded).
• Diagnosis of periodontitis stage II-III or IV (any grade) of periodontitis
• Each participant should have 2 or more contralateral quadrants with a minimum of 4 qualifying pockets of ≥ 5 mm that bled on probing
• Full-mouth parallel periapical X-rays demonstrating bone loss (standard of care)

You may not qualify if:

• Pregnancy (confirmed, suspected, or uncertain), breastfeeding, or intention to become pregnant during the study period
• No antibiotic and periodontal therapy within the last 6 months
• Heavy smoking (more than 10 cigarettes/day)
• Chronic diseases such as uncontrolled diabetes mellitus (HbA1c ≥ 7.0%) or rheumatoid arthritis
• History of radiotherapy or chemotherapy
• Mucosal immune diseases
• Mental disorders
• Parafunctional habits such as bruxism
• Subjects with removable partial dentures
• Patients undergoing orthodontic therapy
• Sites next to recent extraction sockets
• Teeth showing endodontic-periodontic lesions
• Systemically healthy and no known allergies
• Subjects with a known hypersensitivity to hyaluronic acid or to any of the ingredients contained in the product formulation.

Sponsors & Collaborators

• University of Bologna: lead

Study Sites (2)

Centro Odontoiatrico Sforza

Bologna, BO, 40124, Italy

RECRUITING

DIBINEM, Dental Clinic, Periodontology Department, University of Bologna

Bologna, BO, 40125, Italy

RECRUITING

MeSH Terms

Conditions

Periodontal Diseases

Condition Hierarchy (Ancestors)

Mouth Diseases; Stomatognathic Diseases

Central Study Contacts

Martina Stefanini, Dentistry

CONTACT

+390512088181; martina.stefanini2@unibo.it

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Who Masked: PARTICIPANT, INVESTIGATOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Professor

Study Record Dates

• First Submitted: July 21, 2026
• First Posted: July 24, 2026
• Study Start: February 1, 2026
• Primary Completion (Estimated): February 1, 2027
• Study Completion (Estimated): February 1, 2028
• Last Updated: July 24, 2026

Record last verified: 2026-07

Locations

IT (2)